

Global Registration and Life Cycle Management of APIs

Choose 2 out of 3 Parallel Workshops

- Stability Studies and Establishing the Retest Date
- Description of the Manufacturing Process
- Top ten deficiencies in new applications for Certificates of Suitability for chemical purity

SPEAKERS:



Marieke van Dalen Aspen Oss, The Netherlands



Cristian Sampaolesi European Directorate for the Quality of Medicines (EDQM & Health Care), France



Wilhelm Schlumbohm Berlin, Germany



Jan Smeets Centrient Pharmaceuticals, The Netherlands Contents of the regulatory information in the ASMF and CEP

12 - 14 March 2019, Berlin, Germany

LEARNING OBJECTIVES:

- Dossier Requirements for the Drug Substance
- Requirements for the Certificate of Suitability
- Drug Substance Setting Specifications
- Synthesis derived impurities, genotoxic impurities, elemental impurities and residual solvents
- Stability Data
- How to read and use a CEP
- Choice and justification of the API starting material in a submission
- Handling of Variations/Changes in Europe and the US
- Registration procedures in the US, Japan and in emerging countries
- ICH Q3D how to do in practice for APIs



This education course is recognised for the ECA GMP Certification Programme "Certified Regulatory Affairs Manager". Please find details at www.gmp-certification.eu

Global Registration and Life Cycle Management of APIs

12 - 14 March 2019, Berlin, Germany

Objectives

This education course is intended to provide guidance on the format, content and submission procedures for the pharmaceutical documentation of the quality of the drug substance for different types of dossiers, the CTD, the CEP and the European ASMF. In this context the consequences of the guidelines on Elemental Impurities (ICH Q3D(R1)) and genotoxic impurities (ICH M7) will be considered. Furthermore, the impact of the variations regulations will be discussed.

Participants will have the opportunity to choose 2 out of 3 parallel workshops:

- Stability studies and establishing a retest date
- Description of the manufacturing process
- Top ten deficiencies in new applications for Certificates of Suitability for chemical purity

Background

In Europe there are several ways to document the quality of the drug substance for the purpose of marketing authorisation:

- Certificate of Suitability of the pharmacopoeial monograph (CEP)
- Full details of manufacture (according to CTD Module 3 Quality of Drug Substance)
- European Active Substance Master File (ASMF; former Drug Master File, DMF)
- Other evidence of suitability of the pharmacopoeial monograph

In the US, the quality of the drug substance can be documented as part of the CMC Dossier or in a US-DMF.

Target Audience

The education course is designed for all persons involved in the compilation of pharmaceutical dossiers for marketing authorisations who want to become familiar with the different ways to document the quality of the drug substance for the purpose of marketing authorisation in Europe. Furthermore, the course will be of interest to personnel from Quality Units of the pharmaceutical and the API industry.

Programme

Dossier Requirements for the Drug Substance – An Introduction

- Chemical pharmaceutical documentation for active substance(s) Regulatory requirements in EU, USA
- Types of active substances types of documentation
- CTD Module 3, CEP and ASMF (former DMF)
- CEP for a substance for TSE risk assessment

Requirements for the Certificate of Suitability to the European Pharmacopoeia

- Regulatory basis: Resolution AP-CSP (99)4 of the Council of Europe
- CEP Procedure
- Content of the CEP dossier with practical examples
- Administrative minor and major changes, 5-year's revision

Pharmaceutical Impurities: Residual solvents, synthesis-derived and genotoxic and elemental impurities

- CPMP-/ICH-Guidelines on Impurities and Residual Solvents
- ICH M7 Guideline on genotoxic impurities
- ICH Q3D(R1) Guideline on elemental impurities
- Specifying Impurities
- Classifying solvents, setting and proving limits
- Justification of Specification

Stability Data

- CPMP-/ICH-Guidelines
- Stability Summary and Conclusions, stability commitment
- Documentation of Stability Data
- Necessity for documentation of raw data?

How to read and use a CEP

API Regulatory Starting Materials: how to defend their choice in a submission

- Why is this such a hot topic
- What guidelines to consider
- How to define a suitable starting material
- How to defend your choice in the submission
- What is different for generics
- Consequences of a redefinition

Comparison of the CEP and DMF Procedure

- Advantages of the CEP procedure
- Handling Changes
- In which countries is the CEP being accepted?
- Cost Considerations
- Practical examples

Registration procedures in the US and Japan – what are the differences?

The EDQM inspection program

Stability Studies and Establishing the Retest Date Dr Jan Smeets

Description of the Manufacturing Process Dr Wilhelm Schlumbohm

Top ten deficiencies in new applications for Certificates of Suitability for chemical purity Cristian Sampaolesi

Important:

In order to prepare the lectures and the workshops in an optimal way, please send your questions to special topics to Dr Gerhard Becker, becker@concept-heidelberg.de

He will forward your questions to the responsible speaker. Thank you in advance for your cooperation.

Registration requirements for APIs in emerging countries

- General remarks on API registrations in Emerging Countries
- Details of API registration in:
 - China
 - Taiwan
 - India
 - CIS countries: Russia Belarus, Ukraine
 - Brazil
 - GCC countries
- APIC Emerging Countries Interest Group

Variations/Changes and life cycle management: in the EU, US and rest of the world

- Types and categories of API changes
- EU: the variation regulation and CEP revisions
- Handling API changes in the US
- Handling API changes in Japan
- Handling API changes outside these regions
- Initiatives to facilitate changes

ICH Q3D - how to do in practice for APIs

Social Event



In the evening of the first course day, you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.

Speakers



Marieke van Dalen

Aspen Oss B.V., The Netherlands Marieke van Dalen is the global regulatory specialist in the regulatory group dedicated to APIs, with almost 30 years of experience in the regulatory field. She is a board mem-

ber of APIC, the European API Industry organization, and she participates in the Japan task force, Emerging markets task force and the Quality metrics task force. She frequently represents APIC in meetings and conferences organized by EMA, EDQM, ICH etc.

Cristian Sampaolesi



Certification Division, European Directorate for the Quality of Medicines and Healthcare (EDQM), France

Cristian Sampaolesi is a Scientific Officer in charge of the evaluation of new dossiers with

the Certification Division of the EDQM since 2012. From 2003 to 2008 he held different responsibilities in the Quality Control field within the Pharmaceutical Industry in Italy. In 2009 he joined the Maltese National Competent Authority as Quality Assessor, position held for 3 years. From 2010 to 2012 he was the nominated member within the Joint CHMP/CVMP Quality Working Party at EMA.



Dr Wilhelm Schlumbohm *Berlin, Germany*

Dr Schlumbohm worked more than 20 years with German drug licensing authorities in the field of assessment of the CMC parts of new

drug applications. He is expert for the Certification Procedure of the European Pharmacopoeia.

Dr Jan W. H. Smeets



Centrient Pharmaceuticals, The Netherlands Ph.D. in chemistry at the University of Utrecht, The Netherlands; 30 years with the company (Gist Brocades, DSM, DSP, Centrient

Pharmaceuticals) with different positions in Research & Development, Technical Sales Services and Regulatory Affairs for intermediates, APIs and Drug Products. Currently Director Regulatory Affairs within Centrient Pharmaceuticals.and Dutch representative in Expert Group 7 (antibiotics) of the European Pharmacopoeia for 18 years. Author of multiple scientific papers and patents. Member of several interest groups of CEFIC/APIC. Speaker/lecturer in many international conferences/ courses dealing with Regulatory Affairs for APIs.

Easy	Regi	istrat	ion
------	------	--------	-----



Reservation Form: + 49 6221 84 44 34

@ e-mail: info@concept-heidelberg.de

✓ Internet: www.gmp-compliance.org

Oute Date Particle of the comparison of the complexity of	
Reservation form Comparison Reservation form Conformation Reservation form Conform Reservation form Conform Reservation form Conform Reservation form Conterreatenention Rese	
Reservation form (Please complete in full) Reservation for the fully fill (Fill (
Image: Section Son Son Son Son Son Son Son Son Son S	ocu- all
Reservation and Reservation and Reservation and Reservation and Reservation and Reservation and Reservation on Reservation and	room gistered
Reservation and Reservation and Reservation and Reservation and Reservation and Reservation and Reservation on Reservation and	
Reservation and Reservation and Reservation and Reservation and Reservation and Reservation and Reservation on Reservation and	glish.
CONCEPT HEIDELBERG P.O. Box 10 17 64 D-69007 Heidelberg, Germany Phone +49 (0) 62 21/84 44-0 Fax +49 (0) 62 21/84 40 Fax +49 (0) 62 60 Fax +49 (0) 60 Fax +40 60 Fax +40 (0) 60 Fax +40 (0) 60	
CONCEPT HEIDELBERG P.O. Box 10 17 64 D-69007 Heidelberg, Germany Phone +49 (0) 62 21/84 44-0 Fax +49 (0) 62 21/84 40 Fax +49 (0) 62 60 Fax +49 (0) 60 Fax +40 60 Fax +40 (0) 60 Fax +40 (0) 60	n the
التي التي التي التي التي التي التي التي	
t t t t t t t t t t t t t t	
For questions regarding reservation, hotel, organisation etc. please contact: Ms Marion Grimm (Organisation Manager)	
If the bill-to-address deviates from the right, please fill out here: the right of please for the readence out here: the right of please fill out here: the right of pleasend fill out here:	
i right, ral terms and have to out have to in 1 weeks in 1 weeks i	
	/A/2305201